Hyderabad firms partner to develop advanced cancer cell therapy by 2028
- Bharat Biotech's subsidiary Nucelion Therapeutics partnered with Hyderabad-based VeGen Bio on October 21.
- • The partnership focuses on VL-2511, an experimental CAR-T cell therapy for multiple myeloma, a type of blood cancer.
- CAR-T therapy modifies a patient's immune cells to identify & attack cancer cells.
- Companies plan clinical trials in India, targeting commercial availability by 2028.
Source: pharma.economictimes.indiatimes.com
Get 100 stories a day on the app
Read, watch & listen · Free on iOS & Android
